Latest Breaking News On - John trzupek - Page 1 : comparemela.com

Published: Jan 13, 2021 By Brandon May Jonathan Weiss/Shutterstock Major players in the biotech industry are moving full steam ahead in their 2021 operations goals despite the ongoing pandemic, with global pharmaceutical giant Takeda being no exception. The Japanese biopharmaceutical company just announced it has entered into a broad strategic collaboration with KSQ Therapeutics to research, develop and commercialize novel immune-oncology agents using the latter company’s proprietary CRISPRomics® discovery platform. The discovery platform will be used in clinical research to screen the entire human genome in an effort to find optimal gene targets for autoimmune and oncology disease. Under terms of the agreement, Takeda will obtain exclusive, worldwide and royalty-bearing license to develop, manufacturer and commercialize both cell and non-cell therapy candidates for the modulation of targets identified with KSQ’s CRISPRomics platform.

Jonathan weiss shutterstockJonathan weissJohn trzupekDavid baramTakeda ventures incOncology drug discovery unitImmunology unitChief business officerTakeda venturesChief executive officerTakeda operations heat up with new research partnerships and acquisitionsஜொனாதன் வெயிஸ்டேவிட் பரம்டாகேடா முயற்சிகள் இன்க்புற்றுநோயியல் மருந்து கண்டுபிடிப்பு அலகுநோயெதிர்ப்பு அலகு